Oncology Treatment Cycle Visit Note (Pre-Infusion Clearance)

Date/Time: [date and time of visit]

Location: [clinic/infusion center location]

Provider: [clinician name, credentials]

Patient: [name, DOB, MRN]

Diagnosis: [primary malignancy, stage, treatment-determining biomarkers]

Regimen: [protocol name]

Cycle/Day: [cycle and day]

Last Treatment: [last treatment date or "new start"]

Allergies/Prior Reactions: [agents, reaction type, mitigation if relevant]

Reason for Visit

[Pre-infusion clearance statement for specified cycle/day with focus on interval history, toxicities, and labs to determine proceed versus hold or modify] (One to two sentences.)

Interval History & Toxicity

[Interval events since last treatment] (Anchor to time since last infusion. Include hospitalizations, ER visits, infections, fevers, procedures, transfusions, and new concerning symptoms. If key information is unknown or pending, state the uncertainty and how it affects the clearance decision.)

[Current treatment-related toxicities] (Document each with CTCAE grade, attribution [treatment / disease / other], and trajectory [improving / stable / worsening]. Address regimen-relevant domains as appropriate.)

ECOG Performance Status: [0 / 1 / 2 / 3 / 4] (Compare to baseline.)

[Oral therapy adherence] (Include only if regimen has oral components.)

Objective

Vitals: [relevant values as indicated]

Exam: [focused findings pertinent to clearance] (Problem-focused: general appearance, cardiopulmonary, and systems relevant to regimen toxicity profile.)

Labs: [collection date] — [key values relevant to regimen thresholds] (Brief interpretation of decision-critical values or trends; reference protocol thresholds if applicable.)

Other Studies: [study type and date] — [one-line impression] (Include only if new or required this cycle.)

(If required labs or monitoring are pending or missing, explicitly state whether treatment is held pending results or document the exception pathway with justification.)

Assessment

[Brief synthesis of cancer status and tolerance] (State disease status: [responding / stable / progressing] per most recent data. Summarize overall tolerance and key toxicities or risk factors influencing today's decision.)

Clearance Decision: [Okay to treat as planned / Okay to treat with dose modification(s): [specify] / Hold treatment: [reason] / Delay cycle: [reassessment plan] / Discontinue regimen: [rationale and next steps]] (This decision must always be explicitly stated.)

Plan

• Antineoplastic therapy: [regimen, cycle/day, dose modifications with rationale, premedication plan, growth factor plan, antiemetic approach]
• Active toxicity management: [toxicity] — [current management, interventions ordered, hold/resumption criteria for subsequent cycles]
• Supportive care: [hydration, prophylaxis, symptom management, referrals as indicated]
• Monitoring: [next labs with timing, required pre-infusion tests for next cycle, imaging if indicated, follow-up appointment]
• Patient instructions: [red flag symptoms to report, emergency contact, next appointment]
• Medication reconciliation: [completed / updated] (Note relevant changes.)

(Omit sections or lines without available data rather than inserting placeholder text. The Clearance Decision must always be included.)